Nitazoxanide in NASH-Induced Fibrosis

We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models.

NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential treatment of NASH-induced significant liver fibrosis.

For more information, go to clinical trials.gov.

*NTZ is not approved for use in NASH.